Over the past decades, computers and other digital devices have captured vast amounts of health-related data across global patient populations, from electronic health records (EHRs), health insurance claims and billing, product and disease registries, and other diagnostic and health monitoring technologies.

This real-world data (RWD) offers massive potential for the pharma industry and generates real-world evidence (RWE) that is transforming the way contract research organisations (CROs), study sites and health care providers operate.

Piyush Bansal is life sciences senior industry analyst for global research consultancy Frost & Sullivan, and believes RWE will revolutionise the biopharma industry.

“Running a clinical trial can be very time consuming and costly and around 70% of delays are related to patient enrolment and difficulties recruiting a large enough patient population,” he comments. “Often the desired outcomes are still not forthcoming and researchers don’t know about the actual performance of the drugs in a real-world scenario.”

RWE can help address issues of safety and effectiveness more precisely than data gathered from randomised controlled trials (RCT) and optimise return on investment for pharma companies, hence its growing popularity across the industry. Important insights relating to compliance, costs and epidemiology can also be obtained more easily this way.

“With real-world evidence you get to see the results from a much wider population group which helps with better patient outcomes,” Bansal continues. “For example a pharma company might conduct a drug trial with 200 patients, but with RWD you might have access to millions of people’s data so you can better predict the outcome based on their habits, background, ethnicity, genomics, disease profiling and other factors.”

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

With so many advantages, it comes as no surprise that Pfizer is the latest pharma giant to join the real-world data revolution.

TriNetx and Pfizer: a dynamic duo

Pfizer has announced that it will join the TriNetX network, which will offer access to clinical data from a diverse range of healthcare organisations.

TriNetx is a global health research hub that connects pharmaceutical companies, healthcare organisations and CROs to improve trial design, optimise patient recruitment, conduct research and potentially enable new treatments to reach the market faster.

Using TriNetX’s cloud-based platform, researchers can analyse patient populations and carry out ‘what-if’ analyses in real-time. Members are given summated views, but each data point in the TriNetX network is directly linked to healthcare organisations, which are able to identify patients. This enables researchers to set up virtual patient categorisation for potential recruitment into a clinical trial.

“Pfizer joined TriNetX to harness real-world data for clinical trial optimisation, with the goal of accelerating our ability to bring new therapies to market,” explains Dr Mohanish Anand, Pfizer’s head of study optimisation. “Pfizer will use the real-time access to clinical, genomic and oncology data to design clinical trial protocols with greater efficiency.”

TriNetX will help Pfizer to find patients with rare diseases who can be difficult to track down by other means, and to identify sites with patients who meet inclusion and exclusion criteria.

“Our members are liberating data that is trapped within disparate databases all around the world and through our platform we’re able to provide researchers with access to rich, longitudinal and harmonized data,” says Gadi Lachman, CEO at TriNetX. “Pfizer has selected us as a digital partner to help in its strategic initiative to leverage real world data across its organisation, from drug development to outcomes and healthcare research.”

TriNetx made a keynote presentation at the International Society for Pharmacoeconomics and Outcomes Research (ISPOR) 2018 annual meeting, held this May in Maryland, US. The company was keen to herald RWD as an established method for evaluating safety and comparative effectiveness and also entered into a dialogue about other emerging methods.

“Our research shows that answers to very essential scientific questions can be found in real-world data, if you have the right data source, network and methods,” says Manfred Stapff, chief medical officer at TriNetX.

RWD: the challenges of effective analyses across global regions and health systems

Increasingly, RWD is being relied upon by the pharma industry, but challenges and limitations can complicate its use. There may be inconsistencies and gaps in data depending on the methodologies and tools used to collect it. Variations in the quality of clinical practice across global regions and health systems may also make the data less statistically reliable than RCTs and more difficult to interpret and analyse.

“There’s a lot of mixed data available so companies must meet the challenge of how to access and utilise the right kind of information to get insights that are useful,” observes Bansal. “Many of the systems on the market right now do not have adequate tools to analyse RWD effectively.”

Issues around global data sharing are also key.

“There are a lot of additional local requirements,” he continues. “Take Germany and China for example – you cannot take patient data out of those countries, so how do they optimise their efforts based on containing it within those regions?”

The cost of maintaining RWD is also a factor, with many professional and patient groups reliant on government funding, including the UK’s National Health Service. Linked to this is the fundamental issue of the security and anonymity of data.

“We are talking about accessing the data of millions of patients, the EHR and diagnostic data of entire countries,” continues Bansal. “It is essential to make sure all concerned have the technology and expertise to protect that data and ensure there’s no security breach.” 

A future in the real world for RWD and RWE

So what does the future hold for RWD? Bansal predicts that in five to ten years’ time,  RWD and RWE will have completely transformed the industry: “The potential is huge. We will have safer drugs because RWD tells us so much more about how drugs interact with patients in the real world, and the insurance companies like this approach of data-driven decision making for drug approval.”

It will also optimise drug discovery, he says: “Because you can find out and better predict what kind of compounds are working for patients in different environments and understand the related treatment outcome by using RWD. We will see a scenario where end-to-end reliability on data from clinical trials will decline and use of real-world data will go up. RWD and RWE will become essential for drug approval.”